ArticleJournal of gastroenterology2011
Regulation of gastric acid secretion by the serum and glucocorticoid inducible kinase isoform SGK3.
Article in Journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Lack of serum- and glucocorticoid-inducible kinase 3 leads to podocyte dysfunction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe serum and glucocorticoid inducible kinase isoform SGK3 is ubiquitously expressed and has been shown to participate in the regulation of cell survival and transport. Similar to SGK1 and protein kinase B (PKB/Akt) isoforms, SGK3 may phosphorylate glycogen synthase kinase (GSK) 3α,β, which has recently been shown to participate in the regulation of basal gastric acid secretion. The present study thus explored the role of SGK3 in the regulation of gastric acid secretion.
methodsExperiments were performed in isolated glands from gene-targeted mice lacking functional SGK3 (sgk3-/-) or from their wild-type littermates (sgk3+/+). Utilizing 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF) fluorescence, gastric acid secretion was determined from Na(+)-independent pH recovery (∆pH/min) following an ammonium pulse, which reflects H+/K+ adenosine triphosphatase (ATP) ase activity.
resultsCytosolic pH in isolated gastric glands was similar in sgk3-/- and sgk3+/+ mice. ∆pH/min was, however, significantly larger in sgk3-/- than in sgk3+/+ mice. In both genotypes, ∆pH/min was virtually abolished in the presence of the H(+)/K(+) ATPase inhibitor omeprazole (100 μM) and SCH28080 (500 nM). Increase of extracellular K+ concentrations to 35 mM (replacing Na+/NMDG) or treatment with 5 μM forskolin increased ∆pH/min in sgk3+/+ mice to a larger extent than in sgk3-/- mice and abrogated the differences between genotypes. The protein kinase A inhibitor H89 (150 nM) decreased ∆pH/min to similarly low values in both genotypes.
conclusionsSGK3 suppresses gastric acid secretion, an effect presumably mediated by the stimulation of protein kinase A with the subsequent activation of K+ channels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.